Carl June: $3 Million 2024 Breakthrough Prize in Life Sciences
CAR T cell therapy pioneer Carl June, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies (CCI) at Penn Medicine’s Abramson Cancer Center, has been named a winner of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor (CAR) T cell immunotherapy, a revolutionary cancer treatment approach in which each patient’s T cells are modified to target and kill their cancer cells. The invention sparked a new path in cancer care, harnessing the power of patients’ own immune systems, a once-elusive goal that brought fresh options for those who could not be successfully treated with conventional approaches.
Founded in 2012, the Breakthrough Prizes are the world’s largest science awards, with $3 million awarded for each of the five main prize categories. Dr. June is the sixth Breakthrough Prize laureate from Penn, which joins Harvard and MIT among the institutions whose researchers have been honored with the most Breakthrough Prizes.
“This award is not only a testament to Dr. June’s outstanding contributions to science, but also a shining example of the caliber of discoveries and research which Penn faculty set their sights upon,” said University of Pennsylvania President Liz Magill. “We are immensely proud to have Dr. June as a member of the Penn academic community, and we know that CAR T cell therapy is just the first chapter in an inspiring and lifesaving new era of medicine.”
Dr. June is internationally recognized for his role in pioneering the CAR T cell therapy, which led to the first FDA-approved personalized cellular therapy, for children and young adults with the blood cancer known as acute lymphoblastic leukemia, in August of 2017—a step which has spurred five additional approvals of the technique in other blood cancers. Dr. June joined Penn in 1999, building momentum for Penn to become a global hub for cell and gene therapy. Gene-modified T cells engineered in Dr. June’s lab to retrain a patient’s own immune cells to attack cancer were used in the first clinical trial of CAR T cell therapy in 2010. Some of the earliest children and adults treated have experienced long-lasting remissions of 10 years or more. In addition to the FDA approvals that have made the therapy commercially available to patients across the world, thousands more have benefited from clinical trials testing these transformative treatments, including for the treatment of solid tumors and even autoimmune diseases like lupus.
“Dr. June’s tireless commitment to advancing T cell immunotherapy research has been life-changing for many patients affected by cancer, who have lived longer, fuller lives, thanks to the discoveries made in his lab,” said J. Larry Jameson, executive vice president of the University of Pennsylvania for the Health System and dean of the Perelman School of Medicine. “We are proud to see one of Penn’s most esteemed scientists recognized for the impact of his foundational work to develop a new class of cancer immunotherapy treatment.”
In the decades since Dr. June began his CAR T cell research, the field has grown exponentially, with hundreds of CAR T cell clinical trials now in progress worldwide. Dr. June’s lab and the CCI team continue to drive innovation in personalized cell and gene based therapies, developing new strategies to make CAR T cell therapy more effective for all blood cancers, for solid tumors, and even for diseases beyond cancer. He has also made seminal contributions to HIV research, developing the first method to multiply T cells outside the body and showing that the cells could be safely reinfused into the patient, improving the patient’s immune function. These techniques would later be applied to his cancer research.
Dr. June, who is also the director of the Parker Institute for Cancer Immunotherapy at Penn, is a graduate of the U.S. Naval Academy and the Baylor College of Medicine. He has published more than 500 articles and is the recipient of many prestigious scientific achievement awards, including the AACR Award for Lifetime Achievement in Cancer Research, the Keio Medical Science Prize, the Dan David Award, the William B. Coley Award, the Albany Medical Center Prize in Medicine and Biomedical Research, the Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Philadelphia Award, the Taubman Prize for Excellence in Translational Medical Science, the Paul Ehrlich and Ludwig Darmstaedter Prize, the Novartis Prize in Immunology, the Karl Landsteiner Memorial Award, the Sanford Lorraine Cross Award, the Debrecen Award, and a lifetime achievement award from the Leukemia and Lymphoma Society. He is also a member of the National Academy of Medicine and the National Academy of Sciences.
In addition to his scientific accolades, Dr. June has been featured in hundreds of news outlets across the world, was listed in the 2018 TIME 100 list of the most influential people in the world, and is the subject of a documentary film, Of Medicine and Miracles, which made its debut at the 2022 Tribeca Film Festival.
Since its founding in 2013 by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Yuri and Julia Milner, and Anne Wojcicki, the Breakthrough Prize has been given to standout individuals in life sciences, mathematics, and fundamental physics. Along with Dr. June, this year’s recipients are Michel Sadelain, Sabine Hadida, Paul Negulescu, Fredrick Van Goor, Thomas Gasser, Ellen Sidransky, and Andrew Singleton. The laureates will be celebrated April 13, 2024, at the 10th annual Breakthrough Prize ceremony, held in Los Angeles.
Penn researchers Drew Weissman and Katalin Karikó received the 2022 Breakthrough Prize in Life Sciences for their mRNA-based vaccine technology which formed a foundation for the two COVID-19 vaccines deployed across the world beginning in December 2020 (Almanac September 21, 2021). In 2019, the prize went to Penn’s Virginia M.Y. Lee (Almanac September 10, 2019). Two other Penn faculty members, Charles Kane and Eugene Mele, won the 2019 Breakthrough Prize in Fundamental Physics (Almanac October 23, 2018).
President Liz Magill and Provost John L. Jackson, Jr. have announced the appointment of Michael Weisberg as interim director of Perry World House, effective September 1, 2023.
Bob Russell has been named Chief Executive Officer of Penn Presbyterian Medical Center (PPMC), after serving as acting CEO since September 2022. He succeeds Michele Volpe, who was named COO of the University of Pennsylvania Health System (UPHS) in September 2022 following 23 years as PPMC CEO.
Vice Provost for Global Initiatives Ezekiel Emanuel has announced that Kristyn Palmiotto has been appointed executive director of Penn Abroad. Ms. Palmiotto joined the Penn Abroad team seven years ago and most recently served as the department’s deputy director.
Daeyeon Lee has been named the Russell Pearce and Elizabeth Crimian Heuer Professor in the department of chemical and biomolecular engineering in Penn Engineering. Dr. Lee was previously the Evan C Thompson Term Chair for Excellence in Teaching.
Carole Lynn Mercaldo, a former staff member in accounting at Penn’s Division of Facilities and Real Estate Services (FRES), died unexpectedly on July 29. She was 60.
In the 1970s, the United States found itself trying to untangle from the tumult of the previous decade. Despite the civil rights marches, anti-war protests, and social rebellions of the 1960s, progress was seemingly stalled, in particular, progress towards racial equality.
Students, postdocs, alumni, faculty, and staff are all invited to use the Professional Photo Booth in Career Services. Open during normal Career Services business hours (Monday-Friday 9 a.m.-5 p.m.), the booth is a self-serve experience. Visitors can take up to three photos and edit your favorite, all using the touch screen device in the booth or by scanning a QR code with your smartphone. Photos are then delivered by email. Career Services is located in the basement level (suite 20) of the McNeil Building at 3718 Locust Walk.